HomeCompareBAX vs GS

BAX vs GS: Dividend Comparison 2026

BAX yields 2.28% · GS yields 1.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GS wins by $53.75M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
GS
GS
● Live price
1.92%
Share price
$807.60
Annual div
$15.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$53.77M
Annual income
$48,880,568.44
Full GS calculator →

Portfolio growth — BAX vs GS

📍 GS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXGS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + GS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
GS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
GS
Annual income on $10K today (after 15% tax)
$163.14/yr
After 10yr DRIP, annual income (after tax)
$41,548,483.17/yr
At 15% tax rate, GS beats the other by $41,548,474.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + GS for your $10,000?

BAX: 50%GS: 50%
100% GS50/50100% BAX
Portfolio after 10yr
$26.90M
Annual income
$24,440,289.35/yr
Blended yield
90.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GS right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
GS
Analyst Ratings
22
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$915.15
+13.3% upside vs current
Range: $604.00 — $1,100.00
Altman Z
0.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
GS buys
0
No recent congressional trades found for BAX or GS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXGS
Forward yield2.28%1.92%
Annual dividend / share$0.36$15.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%100%
Portfolio after 10y$20.6K$53.77M
Annual income after 10y$10.26$48,880,568.44
Total dividends collected$602.00$53.37M
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldHold
Analyst price target$19.75$915.15

Year-by-year: BAX vs GS ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrGS PortfolioGS Income/yrGap
1← crossover$10,866$166.33$11,084$383.85$218.00GS
2$11,750$123.31$12,655$795.25$905.00GS
3$12,664$90.97$15,238$1,697.15$2.6KGS
4$13,617$66.89$20,124$3,819.72$6.5KGS
5$14,619$49.07$30,962$9,429.13$16.3KGS
6$15,679$35.94$60,246$27,116.14$44.6KGS
7$16,802$26.30$163,084$98,620.80$146.3KGS
8$17,998$19.23$673,498$498,998.66$655.5KGS
9$19,272$14.05$4,572,513$3,851,869.45$4.55MGS
10$20,631$10.26$53,773,157$48,880,568.44$53.75MGS

BAX vs GS: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

GSFinancials

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through four segments: Investment Banking, Global Markets, Asset Management, and Consumer & Wealth Management. The company's Investment Banking segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and middle-market lending, relationship lending, and acquisition financing, as well as transaction banking services. This segment also offers underwriting services, such as equity underwriting for common and preferred stock and convertible and exchangeable securities; and debt underwriting for various types of debt instruments, including investment-grade and high-yield debt, bank and bridge loans, and emerging-and growth-market debt, as well as originates structured securities. Its Global Markets segment is involved in client execution activities for cash and derivative instruments; credit and interest rate products; and provision of equity intermediation and equity financing, clearing, settlement, and custody services, as well as mortgages, currencies, commodities, and equities related products. The company's Asset Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, as well as invests in corporate, real estate, and infrastructure entities. Its Consumer & Wealth Management segment offers wealth advisory and banking services, including financial planning, investment management, deposit taking, and lending; private banking; and unsecured loans, as well as accepts saving and time deposits. The company was founded in 1869 and is headquartered in New York, New York.

Full GS Calculator →
📬

Get this BAX vs GS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.